Search results for "Refractory"

showing 10 items of 253 documents

Isometric muscle contractions after double pulse stimulation. comparison of healthy subjects and patients with myotonic dystrophy.

1996

Isometric contractions of the adductor pollicis muscle were studied in healthy subjects and patients with myotonic dystrophy after single and double stimuli of the ulnar nerve using a wide range of interstimulus intervals (ISI, 0.4-180 ms). In healthy subjects, the force contributed by a second stimulus was greater than the single twitch force being maximal (mean + 140%) at 12-ms ISI. In myotonic dystrophy, the force contributed by the second stimulus was (relative to a reduced twitch amplitude) increased (mean + 204%) with a maximum at 4.8-ms ISI. An abnormal increase of force was only recorded if the single twitch force was clearly reduced. The absolute refractory period of muscle contrac…

AdultMalemedicine.medical_specialtyPhysiologyRefractory periodIsometric exerciseStimulus (physiology)Myotonic dystrophyPhysiology (medical)Internal medicineIsometric ContractionMedicineHumansMyotonic DystrophyOrthopedics and Sports MedicineUlnar nervebusiness.industryPublic Health Environmental and Occupational HealthGeneral MedicineAnatomymedicine.diseaseMyotoniaAdductor pollicis muscleElectric StimulationElectrophysiologyCardiologyFemalemedicine.symptombusinessMuscle contractionEuropean journal of applied physiology and occupational physiology
researchProduct

Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized s…

2020

AbstractIron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient’s perceived quality of life. A new oral iron formulation, Sucrosomi…

AdultMalemedicine.medical_specialtyResuscitationIntravenous sodium ferrigluconateAnemiaCost-Benefit AnalysisHigh dosesAdministration OralHigh dose030204 cardiovascular system & hematologyGastroenterologyFerric CompoundsIntestinal absorption03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryInternal medicineOral Sucrosomial ironMedicineHumans030212 general & internal medicineFerrous CompoundsProspective StudiesAgedAged 80 and overHematologyAnemia Iron-Deficiencybusiness.industryHematologyGeneral MedicineIron deficiencyMiddle Agedmedicine.diseaseIron sulfatechemistryIron-deficiency anemiaIron deficiency anemiaHematinicsAdministration IntravenousFemaleOriginal ArticleRefractoriness/intolerance to oral iron sulfatebusiness
researchProduct

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Predictors of Re‐bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic S…

2018

Abstract Background Transjugular intrahepatic portosystemic shunt (TIPS) has proven clinical efcacy as rescue therapy for cirrhotic patients with acute portal hypertensive bleeding who fail endoscopic treatment. Aims To investigate predictive factors of 6-week and 1-year mortality in patients undergoing salvage TIPS for refractory portal hypertensive bleeding. Methods A total of 144 consecutive patients were retrospectively evaluated. Three logistic regression multivariate models were estimated to individualize prognostic factors for 6-week and 12-month mortality. Log-rank test was used to evaluate survival according to Child–Pugh classes and Bureau’s criteria. Results Mean age 51±10 years,…

AdultMalemedicine.medical_specialtyVariceal bleedingPhysiologymedicine.medical_treatmentPortal venous pressureEsophageal and Gastric VaricesLogistic regressionlaw.inventionCohort Studies03 medical and health sciences0302 clinical medicineRefractoryPredictive Value of TestsRecurrencelawInternal medicinemedicineHumansProspective StudiesMortalityRetrospective StudiesSalvage Therapybusiness.industryGastroenterologyMiddle AgedHepatologyIntensive care unitSurgeryRe bleeding030220 oncology & carcinogenesisTIPSFemale030211 gastroenterology & hepatologyPortasystemic Shunt Transjugular IntrahepaticGastrointestinal HemorrhagebusinessTransjugular intrahepatic portosystemic shunt
researchProduct

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

2011

To evaluate adalimumab therapy in refractory uveitis.Prospective case series.A total of 131 patients with refractory uveitis and intolerance or failure to respond to prednisone and at least 1 other systemic immunosuppressive drug participated.Patients received a 40 mg adalimumab subcutaneous injection every other week for 6 months. The associated immunosuppressants were tapered after administering 3 adalimumab injections (week 6).Degree of anterior and posterior chamber inflammation (Standardization of Uveitis Nomenclature Working Group criteria), immunosuppression load (as defined by Nussenblatt et al), visual acuity (logarithm of the minimal angle of resolution [logMAR]), and macular thic…

AdultMalemedicine.medical_specialtyVisual acuityAdolescentInjections SubcutaneousAnti-Inflammatory AgentsDrug ResistanceVisual AcuityArthritisAntibodies Monoclonal HumanizedUveitisRefractoryPrednisoneInternal medicineAdalimumabMedicineHumansMacula LuteaProspective StudiesPars PlanitisProspective cohort studyChildGlucocorticoidsbusiness.industryTumor Necrosis Factor-alphaAdalimumabOff-Label Usemedicine.diseaseSurgeryOphthalmologyMethotrexateTreatment OutcomeChild PreschoolCyclosporineFemalemedicine.symptombusinessUveitisTomography Optical Coherencemedicine.drugOphthalmology
researchProduct

Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational stu…

2011

Introduction: About 30-40% of patients with acute severe ulcerative colitis (UC) fail to respond to intensive intravenous (iv) corticosteroid treatment. Iv cyclosporine and infliximab are an effective rescue therapy in steroid-refractory UC patients but up to now it is still unclear which is the best therapeutic choice. Methods: We reviewed our series of severe steroid-refractory colitis admitted consecutively since 1994 comparing two historical cohort treated with iv cyclosporine (2 mg/kg) or iv infliximab (5 mg/kg). The main outcome was the colectomy rate at 3 months, 12 months and at the end of the follow-up. Results: A total of 65 patients were included: 35 in the cyclosporine group and…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAnti-Inflammatory AgentsAzathioprineKaplan-Meier EstimateGastroenterologyCohort StudiesRefractoryInternal medicinemedicineHumansColitisColectomyRetrospective StudiesColectomybiologybusiness.industryC-reactive proteinGastroenterologyAntibodies MonoclonalRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyUlcerative colitisInfliximabInfliximabSurgeryLogistic ModelsTreatment OutcomeCyclosporinebiology.proteinColitis UlcerativeFemalebusinessImmunosuppressive AgentsFollow-Up Studiesmedicine.drugJournal of Crohn's and Colitis
researchProduct

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in German…

2013

Objective The objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. Methods The GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response were collected retrospectively. In SLE patients, clinical parameters included tender and swollen joint counts, fatigue, myalgia, general wellbeing, Raynaud’s and the SLEDAI index. Laboratory tests included dsDNA antibody titres, complement factors, hematologic parameters and proteinuria. Finally, th…

AdultMalemyalgiamedicine.medical_specialty610 MedizinCohort StudiesAntibodies Monoclonal Murine-DerivedRheumatologyRefractoryInternal medicineHumansLupus Erythematosus SystemicMedicineIn patientskin and connective tissue diseasesRetrospective Studiesddc:610Proteinuriabusiness.industryOff-Label UseSystemic lupus erythematosus; rituximab; efficacy; safety;Blymphocytes; cohort studiesDiscontinuationCohortPhysical therapyFemaleRituximabmedicine.symptomRituximabbusinessCohort studymedicine.drugLupus
researchProduct

Whole-body MRI radiomics model to predict relapsed/refractory Hodgkin Lymphoma: A preliminary study.

2022

Purpose A strong prognostic score that enables a stratification of newly diagnosed Hodgkin Lymphoma (HL) to identify patients at high risk of refractory/relapsed disease is still needed. Our aim was to investigate the potential value of a radiomics analysis pipeline from whole-body MRI (WB-MRI) exams for clinical outcome prediction in patients with Hodgkin Lymphoma (HL). Materials and methods Index lesions from baseline WB-MRIs of 40 patients (22 females; mean age 31.7 ± 11.4 years) with newly diagnosed HL treated by ABVD chemotherapy regimen were manually segmented on T1-weighted, STIR, and DWI images for texture analysis feature extraction. A machine learning approach based on the Extra T…

AdultPositron emission tomographymedicine.medical_specialtyWhole body mriBiomedical EngineeringBiophysicsVinblastineBleomycinYoung AdultRefractoryRadiomicsPositron Emission Tomography Computed TomographyMachine learningAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRadiology Nuclear Medicine and imagingMagnetic resonance imaging Positron emission tomography Machine learning Texture analysis Hodgkin Lymphomamedicine.diagnostic_testHodgkin Lymphomabusiness.industryMagnetic resonance imagingMetabolic tumor volumeHodgkin DiseaseMagnetic Resonance ImagingDacarbazineTexture analysisPositron emission tomographyDoxorubicinRelapsed refractoryHodgkin lymphomaFemaleRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMagnetic resonance imaging
researchProduct

Changes of sensory conduction velocity and refractory periods with decreasing tissue temperature in man.

1977

Changes with temperature of maximum sensory nerve conduction velocity as well as absolute and relative refractory periods were tested in 14 human subjects. Corresponding to previously published findings maximum conduction velocity decreased with cooling following a Q10 of +1.4. The absolute and relative refractory periods were increased by cooling, the Q10 being -3.1 and -3.35 respectively. There was a tendency showing a more pronounced temperature effect at low temperatures. The Q10 and the steepness of the regressionline changed at the level of 26.9 degrees C, but were significant for the relative refractory period only.

AdultTime FactorsRefractory Period ElectrophysiologicalRefractory periodQ10Neural ConductionSensationAction PotentialsSensory systemElectromyographyNerve conduction velocityBody TemperatureNuclear magnetic resonancemedicineAnimalsHumansRefractory (planetary science)Ulnar NerveTissue temperaturemedicine.diagnostic_testChemistryAnatomyAxonsNeurologyCatsNeurology (clinical)Sensory nerve conduction velocityJournal of neurology
researchProduct

Refractory Acne and 21-Hydroxylase Deficiency in a Selected Group of Female Patients.

2009

<i>Background:</i> Excessive androgen production, suspected in women when acne is accompanied by hirsutism and menstrual irregularities, may be due to congenital adrenal hyperplasia. This inherited disorder of cortisol biosynthesis is caused in more than 90–95% of all cases by 21-hydroxylase deficiency (21-OHD). The steroid 21-hydroxylase gene <i>(CYP21)</i> has a high degree of variability. <i>Objective:</i> This study was conducted to evaluate <i>CYP21 </i>gene mutations in a selected group of women with papulopustular and comedonal acne refractory to treatment, irregular menses and hirsutism. <i>Methods:</i> 30 out of 61 women e…

Adultmedicine.medical_specialtyAdolescentDrug ResistancePhysiologyDermatologyAdrenocorticotropic hormoneYoung AdultSettore MED/38 - Pediatria Generale E SpecialisticaPapulopustularInternal medicineAcne VulgarismedicineHumansPoint MutationCongenital adrenal hyperplasiaGenetic TestingRefractory acne Excessive androgen production Non-classical 21-hydroxylase deficiency CYP21 gene mutations.AcnehirsutismAdrenal Hyperplasia Congenitalmedicine.diagnostic_testbiologybusiness.industry17-alpha-HydroxyprogesteroneACTH stimulation test21-Hydroxylasemedicine.diseasePolycystic ovaryEndocrinologybiology.proteinFemaleSteroid 21-HydroxylaseHyperandrogenismbusinessPolycystic Ovary Syndrome
researchProduct